← All decks

Dermatology

Glucocorticoids

Built from Dermatology, 5th Edition

What’s inside

11 sections · 115 slides

  1. 01

    Overview

    • Scope of this topic

    1 slide

  2. 02

    History and Basic Pharmacology

    From the 1950 Nobel Prize to the chemistry that makes a glucocorticoid active

    • History of glucocorticoid use in medicine
    • Basic chemical structure of glucocorticoids
    • Chemical structure of cortisol (hydrocortisone)
    • Active drugs need a hydroxyl group, not a ketone
    • What the pharmacology table compares
    • Pharmacology of systemic glucocorticoids (GCs).
    • Duration of action shapes drug choice
    • Oral absorption and plasma protein binding

    8 slides

  3. 03

    HPA Axis and Molecular Mechanism

    The body's own cortisol control system, and how the drug switches genes on and off

    • What the HPA axis is
    • Three ways cortisol production is controlled
    • Free glucocorticoid enters the cell
    • Mechanisms of glucocorticoid action
    • How glucocorticoids switch genes on and off
    • What glucocorticoids shut down in inflammation
    • Anti-inflammatory effects of glucocorticoids.
    • Effects on white blood cells

    8 slides

  4. 04

    Routes of Administration in Dermatology

    Choosing oral, intramuscular, intravenous, topical, or intralesional therapy

    • Major dermatologic uses of systemic glucocorticoids
    • Major uses of systemic glucocorticoids in dermatology.
    • Major uses of systemic glucocorticoids in dermatology. (continued)
    • Oral therapy - dosing basics
    • Split dosing and drug choice for oral therapy
    • Intramuscular glucocorticoid therapy
    • Intravenous and pulse glucocorticoid therapy
    • Topical glucocorticoid potency classes
    • Ultra high (super-potent) - WHO class 1
    • Ultra high (super-potent) - WHO class 1 (continued)
    • High potency - WHO class 2
    • High potency - WHO class 2 (continued)
    • High potency - WHO class 3
    • Moderate potency - WHO class 4
    • Moderate potency - WHO class 4 (continued)
    • Moderate potency - WHO class 5
    • Moderate potency - WHO class 5 (continued)
    • Low potency - WHO class 6
    • Low potency - WHO class 7
    • How the vehicle changes potency
    • Avoiding side effects with topical therapy
    • Ophthalmic (eye) glucocorticoid preparations
    • Ophthalmic glucocorticoids.
    • Intralesional glucocorticoid injections

    24 slides

  5. 05

    HPA Suppression, Tapering, and Contraindications

    How to dose, taper, and test the adrenal axis without harming the patient

    • How exogenous glucocorticoids suppress the HPA axis
    • Symptoms and risks of adrenal insufficiency
    • Glucocorticoid withdrawal syndrome
    • Testing the HPA axis
    • When to taper systemic glucocorticoids
    • How fast to taper, by dose range
    • Alternate-morning dosing
    • Alternate-morning glucocorticoid therapy.
    • Contraindications to glucocorticoid therapy

    9 slides

  6. 06

    Overview of Adverse Effects

    Short-term versus long-term toxicity, and who is at higher risk

    • Short-term versus long-term side effects
    • Side effects of short-term systemic glucocorticoid therapy.
    • Categories of long-term glucocorticoid toxicity
    • Major side effects of long-term systemic glucocorticoid therapy.
    • Major side effects of long-term systemic glucocorticoid therapy. (continued)
    • Major side effects of long-term systemic glucocorticoid therapy. (continued)
    • Major side effects of long-term systemic glucocorticoid therapy. (continued)
    • Patients at higher risk for glucocorticoid toxicity
    • Patients at higher risk for toxicity from glucocorticoid (GC) therapy.

    9 slides

  7. 07

    Musculoskeletal and Bone Complications

    Osteoporosis, osteonecrosis, growth suppression, and steroid myopathy

    • Osteoporosis - how common and how fast
    • Why glucocorticoids weaken bone
    • Radiograph showing severe bone demineralization
    • Diagnosing osteoporosis
    • Prevention and treatment algorithm for glucocorticoid-induced osteoporosis
    • Estimating osteoporotic fracture risk with long-term glucocorticoid therapy
    • Medications for glucocorticoid-induced osteoporosis
    • Other bone-protective drug options
    • Osteonecrosis (avascular necrosis)
    • Osteonecrosis of the femoral head
    • Diagnosing and treating osteonecrosis
    • Growth suppression in children
    • Glucocorticoid-related myopathy vs true myositis
    • Myopathy vs myositis: setting, symptoms, and labs
    • Myopathy vs myositis: EMG, MRI, and biopsy

    15 slides

  8. 08

    Eye, Metabolic, Cardiovascular, and GI Effects

    Cataracts, blood sugar and lipid changes, blood pressure, and the gut

    • Cataracts
    • Cataract in a child treated with systemic glucocorticoids
    • Metabolic effects - blood sugar and lipids
    • Other metabolic and body-composition changes
    • Cardiovascular effects
    • Gastrointestinal effects
    • Other GI effects

    7 slides

  9. 09

    Infection and Reproductive Effects

    Susceptibility to infection, vaccine timing, and pregnancy or fertility considerations

    • Increased susceptibility to infection
    • Screening for tuberculosis and Pneumocystis pneumonia
    • Vaccination precautions
    • Obstetric and gynecologic effects
    • Menstrual and fertility effects

    5 slides

  10. 10

    Neuropsychiatric and Cutaneous Effects

    Mood and cognitive change, and the skin's own visible signature of glucocorticoid use

    • Mood and cognitive effects ('steroid psychosis')
    • Risk factors and management of neuropsychiatric effects
    • Pseudotumor cerebri and seizures
    • Cutaneous effects overview
    • Extensive striae from chronic oral prednisone therapy
    • Striae in a second patient on chronic prednisone therapy
    • Cutaneous atrophy from topical glucocorticoids
    • Cutaneous atrophy from chronic topical glucocorticoid use
    • Local side effects of intralesional glucocorticoids
    • Glucocorticoid-induced acne and eruptions
    • Systemic glucocorticoid-induced acne
    • Perioral eruptions from topical and inhaled glucocorticoids
    • Topical and inhaled glucocorticoid-induced perioral eruptions
    • Hypopigmented and rosacea-like perioral eruptions from topical glucocorticoids
    • Topical steroid withdrawal ('steroid addiction')
    • Wound healing and other skin effects

    16 slides

  11. 11

    Drug Interactions and Dose Alterations

    What raises or lowers the dose a patient actually needs

    • Drugs and conditions that require a higher dose
    • Drugs and conditions that require a lower dose
    • Interactions that worsen a specific side effect
    • Effects on other drugs' dose requirements
    • Glucocorticoid (GC) therapy: dosing and side-effect considerations related to drug interactions and medical conditions.
    • Glucocorticoid (GC) therapy: dosing and side-effect considerations related to drug interactions and medical conditions. (continued)
    • Key takeaways
    • References
    • References (continued)
    • References (continued)
    • References (continued)
    • References (continued)
    • Dermatology, 5th Edition (2-Volume Set)

    13 slides